Are Patients with Active Cancer and Those with History of Cancer Carrying the Same Risks of Recurrent VTE and Bleeding While on Anticoagulants?

Direct oral anticoagulants (DOAC) are now recommended for the treatment of cancer-associated thrombosis (CAT) based on the results of dedicated trials demonstrating that DOAC are non-inferior to low molecular weight heparins in preventing recurrent venous thromboembolism (VTE) in this population. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Frere, Corinne, Crichi, Benjamin, Lejeune, Manon, Spano, Jean-Philippe, Janus, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226070/
https://www.ncbi.nlm.nih.gov/pubmed/32283621
http://dx.doi.org/10.3390/cancers12040917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226070/
https://www.ncbi.nlm.nih.gov/pubmed/32283621
http://dx.doi.org/10.3390/cancers12040917

Ejemplares similares